Long-term follow-up of gene-edited immune cell therapy for lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the long-term safety and efficacy of lentiviral-based gene-edited immune cell therapy in patients who have previously received this treatment. Patients who have completed or withdrawn from other treatment protocols can enroll in this follow-up study at any time within 15 years after their last infusion. The study will monitor for delayed adverse events and overall patient outcomes as recommended by health authorities. The focus is on various types of lymphoma, including Diffuse Large B Cell Lymphoma and Follicular Lymphoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients must have ever received Pell's lentiviral-based gene-edited immune cell as monotherapy or as combination therapy in clinical trials.
2. The last lentiviral-based gene-edited immune cell infusion within 15 years.
3. Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

There are no specific exclusion criteria for this study.

Where it's running

• Kaohsiung Medical University Chung-Ho Memorial Hospital
  Kaohsiung, Taiwan, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan, Taiwan Recruiting
• Taipei Veterans General Hospital
  Taipei, Taiwan, Taiwan Recruiting
• Chi Mei Medical Center
  Tainan, Taiwan Recruiting
• Taipei Medical University - Taipei Medical University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Study coordinator: T. Hsun Lin, MSc
• Email: hsun.lin@pellbmt.com
• Phone: 886-2-8791-1789

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• C402 CD19 CAR treatment for relapsed or refractory large B‑cell lymphoma

  We will try an autologous CD19-directed CAR‑T therapy (C402) in adults with relapsed or refractory CD19‑positive large B‑cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Shanghai Exuma Biotechnology Ltd. · Tianjin · NCT06830031

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.